SAROS — clinical trials and the companies behind them
A clinical trial is easy enough to look up. Working out what else is testing the same mechanism, which company sits behind the sponsor name, what its filings say about funding, and whether the dates have moved takes more assembly. The information is spread across registries, regulatory filings, grant records, and usually a spreadsheet holding the pieces together.
I built SAROS to do more of that assembly in one place. It indexes industry-sponsored Phase 1–3 trials on ClinicalTrials.gov with registered primary-completion dates in 2026–2028, then connects them to public records about their sponsors. The calendar is the starting point; underneath it are trial designs, mechanism tags, company financials, selected institutional holdings, insider transactions, regulatory events, and disclosed private funding.
It is free to use, runs in the browser, and is built from public sources. The useful part is being able to move between the biology, the company, and the evidence without rebuilding the same set of searches each time. Open SAROS.
Where it saves work
Build a landscape without starting another spreadsheet. Filter by phase, indication, modality, target, sponsor type, enrollment, or date window. The calendar, charts, and trial list work from the same selection, so you can move from a broad question to the individual studies behind it. An investor can assemble a list for diligence; a research team can see which approaches are already being tested and where its own program sits.
Follow a trial into its company context. Open a dossier to put the study design and mechanism beside available financial, ownership, and regulatory records. This cuts down the repeated work of finding the sponsor, resolving its corporate name, and collecting the same filings. The source links remain available for checking the associations and reading the detail.
Find related programs. Target and mechanism tags let you search across records whose titles use different drug names or development codes. Programs & peers compares sponsors by their registered trial portfolios. That is a useful starting set for a closer comparison of mechanisms, populations, and endpoints; similarity in a trial portfolio does not establish therapeutic equivalence.
Review changes rather than rereading the whole registry. A daily job re-pulls the registry, regulatory dates, filings and prices against Monday's snapshot, so the diff accumulates through the week: new records, moved dates, status changes, and changed primary-outcome text, with the registry versions the sponsor saved since. The same list is published as changes.json and an RSS feed at changes.xml. Watchlists keep a set of trials together, and CSV export carries the selected rows into your own analysis.
The time saving comes from reusing the search, matching, filtering, and comparison work. SAROS gets the relevant records onto the same screen so more of the effort can go toward interpreting them.
How it compares with other tools
SAROS overlaps with several familiar research workflows. Its scope is the public information that can be assembled around a registered trial; dedicated platforms add their own coverage, curation, and analysis.
| Tool or workflow | What overlaps | Where the scope differs |
|---|---|---|
| ClinicalTrials.gov, EDGAR, NIH RePORTER, and a spreadsheet | Trial searches, filing lookups, sponsor matching, and lists of programs to follow | SAROS combines the covered records and carries a selection between views. The original sources remain the place to verify a result and read the full record. |
| Benzinga's FDA calendar | Browsing upcoming regulatory events by company and drug | SAROS adds a registry-based trial landscape, sponsor context, and the dates companies guide to in their own 8-K and 6-K filings. Its main date field is primary completion, which must be distinguished from an announced catalyst. |
| Biomedtracker | Exploring development programs and clinical or regulatory events | Biomedtracker includes proprietary approval metrics and analyst commentary. SAROS uses public records and explicit heuristics; it does not reproduce that analytical coverage. |
| Citeline Trialtrove | Filtering trials and comparing the clinical landscape | Trialtrove provides curated intelligence for trial planning and benchmarking. SAROS offers a narrower view of registered studies within its date window, connected to company records. |
| PitchBook | Looking at companies, investors, and financing activity | SAROS surfaces available Form D filings, NIH awards, and selected public-market holdings. It does not supply a comprehensive private-market database, valuations, or cap tables. |
For an initial landscape or a list of programs to investigate, SAROS can replace much of the manual assembly across public sites. For analyst assessments, comprehensive deal coverage, or specialized trial planning, those broader platforms provide capabilities beyond its scope.
What the dates and scores mean
Readout. The calendar uses the registered primary-completion date: the completion of data collection for the primary outcome measures. A company may report interim results earlier or publish its main analysis later. An ACTUAL registry date confirms the recorded completion event, not an announcement date. Month-only dates and concentrations at half-year boundaries warrant checking against company guidance.
Regulatory events. PDUFA, advisory-committee, and resubmission events are extracted from company filings, with links to the source passages. Check the asset, indication, and event in the filing; an extracted date can be associated with the wrong nearby drug name.
Confidence. A rules-based score summarizing evidence about the registered date. It is not a calibrated probability that results will arrive on schedule or that the trial will succeed.
Prior. An approximate historical phase-transition rate, separating oncology from non-oncology. It describes advancement from a phase, not the cumulative probability of approval; the rNPV sketch is pre-filled with that cumulative figure instead, and it is editable, so its approval probability and commercial assumptions need to be set for the question being modeled.
Financial context. Cash and investments come from the company's own XBRL facts at one balance-sheet date, counting every investment tag the filer uses; the dossier names the tags and the period. Burn is operating cash flow annualized from the year-to-date figure in the same filing, with the fiscal-year figure and then the annualized net loss as labelled fallbacks. Debt is shown beside cash and is not netted from it. Filings after the balance-sheet date, including financings, are listed but are not in the cash figure. Market cap is a dated last close from an unofficial quote endpoint times cover-page shares; where no quote is available the SEC public float is shown instead and marked as such.
Impact and flags. Impact is an ordered rule score over phase, prior, size, date firmness, and crowding. The flag column shows the first rule that fired for a record: Stopped, Cash flag, Date passed, Date unconfirmed, Date slipped, Specialist adds, Insider buys, Enrollment lag, Pivotal with an actual date, Pivotal inside six months, or No flag. They are descriptive labels for triage, not position recommendations, and their false-positive rates are not yet measured; a labelled evaluation is the next piece of work.
Sources and refresh
| Source | Used for |
|---|---|
| ClinicalTrials.gov API v2 | Trial dates, status, design, enrollment, sites, interventions, and summaries |
| SEC EDGAR filings | Disclosed regulatory events and their supporting passages |
| SEC XBRL company facts | Cash, every investment tag the filer uses, debt, year-to-date operating cash flow, shares, and public float, one document per matched issuer |
| SEC EDGAR submissions | Financing forms, ownership schedules, 8-Ks, and periodic reports filed since the balance sheet |
| SEC EDGAR full-text search (8-K, 6-K) | Company-guided milestones: dated sentences about topline data, interim analyses, enrollment, and study starts |
| SEC 13F filings | Reported holdings of the selected funds covered by SAROS |
| FINRA short interest | Shares short and days to cover at the latest settlement |
| ClinicalTrials.gov version history | Registry versions saved since the weekly snapshot, for changed trials |
| Yahoo chart and Nasdaq quote endpoints | Last close, dated; unofficial, used for market cap only |
| SEC insider-transaction datasets | Reported open-market purchases and sales |
| SEC Form D datasets | Disclosed securities offerings, amounts sold, and related filing details |
| NIH RePORTER | Research awards associated with matched organizations |
| openFDA Drugs@FDA | Approval actions |
| Wong, Siah & Lo (2019) | Historical phase-transition reference rates |
The registry, regulatory calendar, filings, prices, and version history are re-pulled daily; the full build, including company facts, ownership, insiders, Form D, NIH awards, and guided milestones, is rebuilt weekly. The in-app Method tab opens with a table of what each loader last pulled and how many rows reached the build. Reporting periods still matter: a newly retrieved quarterly holding is a record of that quarter, and a Form D filing describes a disclosed offering rather than a company's complete financing history.
Coverage depends on registration, disclosure, and successful matching. Missing information can mean no public record, a record outside the dataset, or an unresolved association. It should not be read as proof that a company has no funding, no investors, or no competing program.
Why SAROS
The name comes from the repeating eclipse cycle. The calendar and eclipse mark borrow that idea of keeping track of events over time. In drug development the dates are considerably less cooperative, which is part of the reason to keep the record.
Built and maintained by Giovanni Carosso. Source on GitHub, Apache-2.0. Nothing on this site is investment advice.